Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Published:2021-12-16 Issue:12 Volume:7 Page:e214761
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Zhou Caicun¹,Ramalingam Suresh S.²,Kim Tae Min³,Kim Sang-We⁴,Yang James Chih-Hsin⁵,Riely Gregory J.⁶,Mekhail Tarek⁷,Nguyen Danny⁸,Garcia Campelo Maria R.⁹,Felip Enriqueta¹⁰,Vincent Sylvie¹¹,Jin Shu¹¹,Griffin Celina¹¹,Bunn Veronica¹¹,Lin Jianchang¹¹,Lin Huamao M.¹¹,Mehta Minal¹¹,Jänne Pasi A.¹²

Affiliation:

1. Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, China

2. Winship Cancer Institute of Emory University, Atlanta, Georgia

3. Seoul National University Hospital, Seoul, South Korea

4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

5. National Taiwan University Cancer Center, Taipei, Taiwan

6. Memorial Sloan Kettering Cancer Center, New York, New York

7. AdventHealth Orlando, Orlando, Florida

8. Pacific Shores Medical Group, Long Beach, California

9. Complejo Hospitalario Universitario A Coruña Hospital Teresa Herrera-Materno Infantil, A Coruña, Spain

10. Vall d’Hebron University Hospital, Barcelona, Spain

11. Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts